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Abstract
Background: Rosiglitazone (ROZ) and glimepiride (GLM) are antidiabetic agents used in the treatment of type 2
diabetes mellitus. A survey of the literature reveals that only one spectrophotometric method has been reported
for the simultaneous determination of ROS and GLM in pharmaceutical preparations. However the reported
method suffers from the low sensitivity, for this reason, our target was to develop a simple sensitive HPLC method
for the simultaneous determination of ROZ and GLM in their combined dosage forms and plasma.
Results: A simple reversed phase high performance liquid chromatographic (RP-HPLC) method was developed and
validated for the simultaneous determination of Rosiglitazone (ROS) and Glimepiride (GLM) in combined dosage
forms and human plasma. The separation was achieved using a 150 mm × 4.6 mm i.d., 5 μm particle size
Symmetry
® C18 column. Mobile phase containing a mixture of acetonitrile and 0.02 M phosphate buffer of pH 5
(60: 40, V/V) was pumped at a flow rate of 1 mL/min. UV detection was performed at 235 nm using nicardipine as
an internal standard. The method was validated for accuracy, precision, specificity, linearity, and sensitivity. The
developed and validated method was successfully used for quantitative analysis of Avandaryl™ tablets. The
chromatographic analysis time was approximately 7 min per sample with complete resolution of ROS (tR = 3.7
min.), GLM (tR = 4.66 min.), and nicardipine (tR, 6.37 min). Validation studieswas performed according to ICH
Guidelines revealed that the proposed method is specific, rapid, reliable and reproducible. The calibration plots
were linear over the concentration ranges 0.10-25 μg/mL and 0.125-12.5 μg/mL with LOD of 0.04 μg/mL for both
compounds and limits of quantification 0.13 and 0.11 μg/mL for ROS and GLM respectively.
Conclusion: The suggested method was successfully applied for the simultaneous analysis of the studied drugs in
their co-formulated tablets and human plasma. The mean percentage recoveries in Avandaryl™ tablets were
100.88 ± 1.14 and 100.31 ± 1.93 for ROS and GLM respectively. Statistical comparison of the results with those of
the reference method revealed good agreement and proved that there were no significant difference in the
accuracy and precision between the two methods respectively. The interference likely to be introduced from some
co-administered drugs such as glibenclamide, gliclazide, metformine, pioglitazone and nateglinide was investigated.
Keywords: HPLC, rosiglitazone (ROS), glimepiride (GLM), human plasma
* Correspondence: nelenany1@yahoo.com
1Department of Analytical Chemistry, Faculty of Pharmacy, University of
Mansoura, Mansoura, 35516, Egypt
Full list of author information is available at the end of the article
El-Enany et al. Chemistry Central Journal 2012, 6:9
http://journal.chemistrycentral.com/content/6/1/9
© 2011 El-Enany et alBackground
Rosiglitazone (ROZ), 5-((4-(2-(methyl-2-pyridinylamino)
ethoxy)phenyl)methyl)-2,4-thiazolidinedione (Figure 1) is
a thiazolidinedione antidiabetic agent used in the treat-
ment of type 2 diabetes mellitus. It exerts its effect
through the peroxisome proliferator-activated receptor-
gamma, which facilitates the expression of genes respon-
sible for glucose and lipid metabolism [1].
Regarding glimepiride (GLM), 3-ethyl-4-methyl-N-(4-
[N-((1r,4r)-4 methylcyclohexylcarbamoyl)sulfamoyl]phe-
nethyl)-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide
(Figure 1) it is a medium-to-long acting sulfonylurea
anti-diabetic drug. It is the first of the third-generation
sulfonylurea, and is very potent [2].
The two drugs are co-formulated commercial tablets
which is used for the treatment of patients with type 2
diabetes:
Literature survey reveals few analytical methods for
the determination of rosiglitazone (ROS) in pharma-
ceutical preparations and biological fluids, including:
spectrophotometry [3,4], voltammetry [5] and HPLC
[6-8].
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Figure 1 Structural formulae of the studied drugs.
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Page 2 of 10As for glimepiride, several methods have been pub-
lished concerning its analysis in formulations and biolo-
gical fluids Viz; spectrophotometry [9], polarography
[10] and HPLC [11-13].
To the best of our knowledge in recent years only one
spectrophotometric method has been reported for the
simultaneous determination of ROS and GLM in pharma-
ceutical preparations [14]. However the reported method
suffers from the low sensitivity, for this reason, our target
was to develop a simple sensitive HPLC method for the
simultaneous determination of ROZ and GLM in their
combined dosage forms and plasma. Because HPLC meth-
ods have been widely used for routine quality-control
assessment of drugs, because of their sensitivity, repeat-
ability, and specificity, we have developed a simple and
specific RP-HPLC method for simultaneous determination
of ROS and GLM in pharmaceutical dosage forms.
Because analytical methods must be validated before use
by the pharmaceutical industry, the proposed HPLC-UV
method was validated in accordance with International
Conference on Harmonization (ICH) guidelines [15], by
assessing its selectivity, linearity, accuracy, precision, and
limits of detection and quantitation.
Experimental
Instruments
Chromatographic System and Conditions
The HPLC system is LC-10A (Shimadzu, Kyoto, Japan)
consisted of a pump (LC-10), UV detector (SPD-10AV)
and auto-injector (SIL-10 AXL).
Column: Symmetry
® C18 (150 mm × 4.6 mm i.d., 5
μm particle size), Waters, Ireland. The column hold up
value was the first deviation of the base line obtained.
Mobile phase: consists of a mixture of acetonitrile and
0.02 M phosphate buffer of pH 5 (60: 40, V/V). The run
time was 8 min at a flow rate was 1 ml min
-1., detector
wavelength 235 nm. The injection volume was 30 μl.
Materials and reagents
All materials and reagents used were of Analytical
Reagent grade.
-Rosiglitazone maleate reference standard was kindly
supplied by Glaxo SmithKline, Egypt
- Glimepiride reference standard was kindly supplied
by Delta Pharma, Egypt.
-Avandaryl™ tablets; labeled to contain 4 mg rosiglita-
zone maleate and 2 mg glimepride per tablet, were pur-
chased from commercial sources in the local market.
-Acetonitrile, methanol, ethanol and propanol (Sigma-
Aldrich, Germany).
- S o d i u md i h y d r o g e np h o s p h a t ea n dd i s o d i u mh y d r o -
gen phosphate (Winlab, England).
-Human plasma was kindly provided by Mansoura
University Hospitals, Mansoura, Egypt and was kept fro-
zen until used after gentle thawing.
Standard solutions
Stock solutions of ROS, GLM and nicardipine were pre-
pared by dissolving 20 mg of each pure substance in
1 0 0m Lo fm e t h a n o lt oo b t a i nas t o c ks o l u t i o no f
200 μg/mL. These stock solutions were further diluted
with the same solvent and then with the mobile phase
as appropriate to obtain the working standard solution
of 0.10-25 μg/mL and 0.125-12.5 μg/mL for ROS,
GLM respectively). The solutions were stable for at
least three days without alteration when kept in the
refrigerator.
General procedures for analysis of laboratory prepared
mixture of ROS and GLM
Aliquot volumes containing ROS, GLM and nicardipine
(IS) were quantitatively transferred into a series of 10
mL volumetric flasks, so that the final concentration
were in the range of 0.10-25, 0.125-12.5 and 20 μg/mL
for ROS, GLM and NIC (IS) respectively. The solutions
were completed to the volume with the mobile phase.
30 μL aliquots were injected (in triplicate) and the cali-
bration curve was constructed by plotting the peak area
ratio against the final concentration of the drug (μg/
mL). Alternatively the corresponding regression equa-
tions were derived.
Application of the proposed method to the analysis of
Avandaryl™ tablets
Ten Avandaryl™ tablets were weighed and pulverized
well. A weighed quantity of the powder equivalent to
20.0 mg of ROS and 10 mg of GLM were transferred
into a small conical flask and extracted three successive
times each with 30 mL of methanol. The extracts were
filtered into 100 mL volumetric flask. The conical flask
and filter paper were washed with few milliliters of
methanol. The washings were passed into the same
volumetric flask, and completed to volume with same
solvent. Aliquots covering the working concentration
ranges were transferred into 10 ml volumetric flasks.
The procedures described under “General procedures”
were performed. The nominal contents of the tablets
were calculated using the corresponding regression
equations.
Application of the proposed method to spiked human
plasma
Blank plasma was spiked with standard solutions of both
drugs to achieve the following calibration standard con-
centrations 0.1- 0.25- 0.5- 0.75 and 1.0 μg/mL; for both
of ROS and GLM respectively at constant concentration
of NIC (2 μgm L
-1).
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ing concentrations of the drugs were transferred into
centrifugation tubes. Acetonitrile (2 ml) was added to
each tube. After vortex mixing for 5 min., the mixtures
were centrifuged at 3500 rpm for 15 min. at room tem-
perature. The Supernatant was evaporated using nitro-
gen gas in a heating block set at 45°C. Dried samples
were reconstituted with the mobile phase and. Aliquots
of 30 μL were injected (triplicate) and eluted with the
mobile phase under the reported chromatographic con-
ditions. A blank experiment was carried out simulta-
neously. The peak area ratio was plotted versus the
concentration of the drugs in μgm L
-1 to get the calibra-
tion graph. Alternatively, the regression equations were
derived.
Results and Discussion
After extensive various preliminary experimental trials
using different combinations of buffers, organic modi-
fiers (acetonitrile methanol, ethanol and propanol), and
after trials using different C8 and C18 reverse pharsed-
phase (RP) columns, best chromatographic conditions to
obtain good separation, resolution and symmetrical
peaks for simultaneous determination ROS and GLM
were achieved when using a mobile phase mixture of
acetonitrile and 0.02 M phosphate buffer of pH 5 (60:
40, V/V). The run time was 8 min at a flow rate was 1
mL/min. and detector wavelength 235 nm. The injection
volume was 30 μL. Moreover the proposed method
allowed the simultaneous determination of ROS and
GLM. in their co-formulated tablets and in human
plasma. Figure 2 shows a typical chromatogram of mix-
ture of ROS and GLM indicating complete resolution of
ROS (tR = 3.7 min.) and GLM (tR = 4.66 min.), and
nicardipine (tR, 6.37 min).
Chromatographic condition and optimization
Choice of column
Trials were performed using Symmetry
® C18 column
(150 mm × 4.6 mm i.d., 5 μm particle size), Waters, Ire-
land; Zorbax SB-Phenyl column (250 mm × 4.6 mm i.d.,
5 μm particle size), Agilent Technologies, USA, and
Hypurity C8 column (250 mm × 4.6 mm i.d., 5 μmp a r -
ticle size). Thermo Electron Corporation. The experi-
mental studies revealed that the first column was the
best one, since it produced symmetrical peaks with high
resolution. The phenyl column resulted in separation of
both drugs but with low resolution for ROS (tR =3 . 1
min.) and GLM (tR = 3.69 min.). On the other hand
using C8 column resulted in separation of both drugs
but with low sensitivity for ROS (tR = 3.4 min.) and
GLM (tR = 4.2 min.)
(ROS)
(GLM)
(NIC)
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Figure 2 Typical chromatogram of glimepiride (12.5 μgm L
-1), rosiglitazone (25 μgm L
-1) and nicardipine HCl (20 μgm L
-1)u s i n g
acetonitrile/0.02 M phosphate buffer of pH 5 (60: 40, V/V) as a mobile phase.
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Several modifications in the mobile phase composition
were performed in order to study the possibilities of
improving the performance of the chromatographic sys-
tem. These modifications included: the type and ratio of
the organic modifier, effect of flow rate and the pH
Type of organic modifier
Acetonitrile was replaced by methanol, ethanol and pro-
panol. Although ethanol and propanol gave sharp peaks,
yet they were not selected as using ethanol gave longer
retention time and propanol resulted in poor resolution.
Methanol on the other hand gave very small and broad
peaks. In addition, the three organic modifiers showed
low sensitivity. So, acetonitrile was the organic modifier
of choice giving symmetrical highly sensitive peaks in a
reasonable time.
Ratio of organic modifier
The effect of changing the ratio of organic modifier on
the retention times and resolution of the tested solutes
was investigated using mobile phases containing concen-
trations of 40-70% (V/V) of acetonitrile. It was found
that, the retention times of both drugs decreased upon
increasing the ratio of acetonitrile up to 70% (V/V).
However, the study revealed that the optimum chroma-
tographic separation was achieved upon using 60%
acetonitrile regarding sensitivity and separation within a
reasonable time (Figure 3). Although 70% concentration
gave the highest resolution values, yet it was not
selected as it resulted in poor separation and non sym-
metrical peaks.
Effect of pH
As it is well known that the buffer is important during
the liquid chromatographic phase because it allows for
the separation of organic compounds, 0.02 M phosphate
buffer was chosen a buffer as it is very handy with better
solubility in organic solvents.
The effect of pH of the mobile phase on the retention
times and the number of theoretical plates for the tested
solutes was investigated using mobile phases of 0.02 M
phosphate buffer with pH ranging from 2.6-6.0. It was
found that, increasing the pH would increase the retention
time of each of ROS and GLM respectively up to pH 5.0.
Beyond pH 5, the retention time decreased. Figure 4 illus-
trates that pH 5.0 was the most appropriate one giving well
resolved peaks with the highest number of theoretical plates.
Flow rate
The effect of flow rate on the formation and separation
of peaks of the studied compounds was studied and a
flow rate of 1 mL/min. was the optimal for good separa-
tion in a reasonable time.
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Figure 3 Effect of acetonitrile: phosphate buffer ratio (pH 5.0) on the resolution of GLM (12.5 μgm L
-1)a n dR O S( 2 5μgm L
-1)u s i n g
the proposed HPLC method.
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Linearity
Under the above described experimental conditions, a
linear relationship was established by plotting the peak
area ratio against the drug concentration. The relation-
ship was found to be rectilinear over the range 0.10-25
μg/mL and 0.125-12.5 μg/mL for ROS and GLM respec-
tively. The results are abridged in Table 1. Linear
regression analysis of the data gave the following equa-
tions:
PA = −5.9 × 10−4 + 0.119C (r = 0.9999)for ROS
PA = −1.7 × 10−3 + 0.122C (r = 0.9999)forGLM
Where: PA is the peak area ratio, C is the concentra-
tion of the drug in μg/ml and r is the correlation
coefficient.
Limit of quantitation (LOQ) and limit of detection (LOD)
The limit of quantitation (LOQ) and the limit of detec-
tion (LOD) were calculated according to ICH guidelines
(ICH Topic Q2B 2004) [15] using the following equa-
tions: [15]
LoQ = 10Sa/bandLoD = 3.3Sa/b
Where Sa is the standard deviation of the intercept of
the regression lines and b is the slope of the calibration
curve.
LoQ values were found to be 0.13 and 0.11 μg/mL for
R O Sa n dG L M ,r e s p e c t i v e l y ,w h i l eL o Dv a l u e sw e r e
found to 0.04 μgm L
-1 for both compounds.
Statistical evaluation of the regression lines regarding
standard deviation of the residual (Sy/x), standard devia-
tion of the intercept (Sa) and standard deviation of the
slope (Sb) is shown in Table 1. The small values of the
figures point out to the low scattering of the points
around the calibration curve (Table 1) thus indicating
high precision of the method [16].
The proposed method was evaluated by studying the
accuracy as percent relative error (%Er) and precision as
percent relative standard deviation (%RSD). The results
are abridged in Table 1.
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Figure 4 Effect of pH on the resolution of GLM (12.5 μgm L
-1) and ROS (25 μgm L
-1) using the proposed HPLC method.
Table 1 Analytical performance data for the
determination of the studied drugs by the proposed
method.
Parameter ROS GLM
Linearity range (μg/mL) 0.10-25 0.125-12.5
Intercept (a) -5.9 × 10
-4 -1.7 × 10
-3
Slope (b) 0.119 0.122
Correlation coefficient (r) 0.9999 0.9999
S.D. of residuals (Sy/x) 6.90 × 10
-3 2.68 × 10
-3
S.D. of intercept (Sa) 1.58 × 10
-3 1.39 × 10
-3
S.D. of slope (Sb) 2.88 × 10
-4 2.36 × 10
-4
Percentage relative standard deviation, % RSD 0.80 0.92
Percentage relative error, % Error 0.28 0.35
Limit of detection, LOD (μg/mL) 0.04 0.04
Limit of quantitation, LOQ (μg/mL) 0.13 0.11
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The accuracy of analytical method is defined as the similar-
ity of the results obtained by this method to the true value
and the precision as the degree of that similarity [16].
To prove the accuracy of the proposed method, the
results were compared with those obtained using the
reference method [14]. Moreover, several synthetic mix-
tures of ROS and GLM in different concentrations were
also analyzed. Statistical analysis of the results obtained
using Student’s t-test and variance ratio F-test [16]
revealed no significant difference between the perfor-
mance of the two methods regarding the accuracy and
precision, respectively (Table 2).
The proposed procedure offers additional advantages
over the reference procedure [14] in that the former is
more sensitive with good accuracy and precision. The
latter method depends on the analysis of ROS-GLM
b i n a r ym i x t u r eb yf i r s td e r i vative spectrophotometric
technique up to the concentration of 30 μg/mL.
Pharmaceutical application
Dosage form analysis The proposed method was
further applied to the determination of the studied
drugs in their co-formulated tablets. The results
shown in Table 2 are in good agreement with those
obtained with the reference method [14]. Statistical
analysis of the results obtained using Student’st - t e s t
and variance ratio F-test [16] revealed no significant
difference between the performance of the two meth-
ods regarding the accuracy and precision, respectively
(Table 2).
The selectivity of the method was investigated by
observing any interference encountered from common
tablet excipients such starch, magnesium stearate, lac-
tose and avisil. It was shown that these compounds did
not interfere with the results of the proposed method.
Biological application
The high sensitivity of the proposed method allowed the
determination of rosiglitazone in spiked human plasma.
The absolute bioavailability of rosiglitazone is 99%. Fol-
lowing single oral administration of rosiglitazone 8 mg
to fasting diabetic patient, a mean peak plasma concen-
tration of 0.117 μg/mL was observed [17]. This concen-
tration lies within the linear concentration range of the
proposed method.
Table 2 Assay results for the determination of the studied drugs in their synthetic mixture and co-formulated tablets.
Sample Concentration taken
(μg/mL)
Concentration found
(μg/mL)
% Found Reference method
[14]
1- Synthetic mixture(a) ROS GLM ROS GLM ROS GLM ROS GLM
0.25 0.125 0.249 0.127 99.60 101.60 99.10 100.27
0.5 0.25 0.501 0.251 100.20 100.40 100.64 98.18
1.0 0.5 1.013 0.506 101.30 101.20 98.00 99.73
5.0 2.5 4.966 0.473 99.32 98.92
10.0 5.0 10.005 5.014 100.05 100.28
15.0 7.5 15.131 7.473 100.87 99.64
25.0 12.5 25.047 12.473 100.19 99.78
X’ 100.22 100.26 99.25 99.06
SD 0.68 0.92 1.33 1.08
%RSD 0.68 0.92
±%Error 0.26 0.35
t- test 1.58 1.80
F- test 3.83 1.37
2-AvandarylTM tablets(b) (4 mg ROS + 2 mg GLM/tablet) 0.25 0.125 0.253 0.123 101.20 98.40 98.10 101.56
1.0 0.5 0.994 0.511 99.4 102.20 99.27 98.50
5.0 2.5 5.038 2.543 100.76 101.72 100.71 100.40
10.0 5.0 10.215 4.946 102.15 98.92
X’ 100.88 100.31 99.36 100.15
SD 1.14 1.93 1.31 1.54
%RSD 1.14 1.93
±%Error 0.57 0.97
t- test 1.65 0.12
F- test 1.32 1.32
N.B.:
(a) The values of tabulated t and F are (2.31) and (5.14) respectively at p = 0.05
(b) The values of tabulated t and F are (2.57) and (9.550 respectively at p = 0.05
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glimipride, a mean plasma level of 0.176 μg/mL was
achieved at 2.1 hour [18].
The interference arising from the endogenous amino
acids has been overcome by simple precipitation of
protein. The method just involved simple plasma protein
precipitation with acetonitrile prior to measurement [19].
Figure 5 shows the typical chromatogram of studied
d r u g so b t a i n e df r o ms p i k e dp l a s m a .T a b l e3s h o w st h e
results obtained from spiked plasma. Under the above
(ROS) (GLM) (NIC)
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Plasma peak
Plasma peak
Dete
ctor respon
s
e
Dete
ctor respon
s
e
Figure 5 Typical chromatogram for: (A): Blank plasma (B): ROS (1 μgm L
-1), GLM (1 μgm L
-1)a n dN I C( 2μgm L
-1) in spiked human
plasma.
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was established by plotting the peak area ratio against
the drug concentration. Linear regression analysis of the
data gave the following equations:
PA = −7.9 × 10−3 + 1.142C (r = 0.9998)
for ROS,.....
PA = −0.0197 + 1.173C (r = 0.9998)
for GLM respectively
Where: PA is the peak area ratio, C is the concentra-
tion of the drug in μg/mL and r is the correlation
coefficient.
The high value of the correlation coefficient (r) indi-
cates the good linearity of the calibration graph.
Precision of the proposed method in spiked human plasma
The intra-day precision was evaluated through replicate
analysis of plasma samples spiked with different concen-
trations of ROS and GLM in one day. The mean %
Table 3 Application of the proposed method to the determination of the studied drugs in spiked human plasma.
Compound Concentration taken (μg/mL) Concentration found (μg/mL) % Found
Rosiglitazone 0.10 0.1058 105.80
0.25 0.2398 95.92
0.50 0.5017 100.34
0.75 0.7574 100.99
1.0 0.9964 99.64
X’ 100.54
±S D ± 3.54
% RSD 3.52
% Error 1.57
Glimepiride 0.10 0.1072 107.20
0.25 0.2487 99.48
0.50 0.4925 98.50
0.75 0.7440 99.20
1.0 1.008 100.80
X’ 101.04
±S D ± 3.55
% RSD 3.51
% Error 1.57
Table 4 Validation data for the HPLC analysis of ROS and GLM in spiked human plasma.
Parameters Concentration added (μg/mL) Concentration found (μg/mL) % Found
ROS GLM ROS GLM ROS GLM
Intra-day precision 0.5 0.5 0.4794 0.5033 95.88 100.66
0.75 0.75 0.7282 0.7157 97.09 95.43
1.0 1.0 1.0013 0.9821 100.13 98.21
(x) 97.70 98.10
± S.D. 2.19 2.62
%RSD 2.24 2.67
%Error 1.29 1.54
Inter-day precision 1
st day 0.5 0.5 0.4769 0.459 95.38 91.80
2
nd day 0.75 0.75 0.7457 0.719 99.43 95.87
3
rd day 1.0 1.0 0.9677 0.939 96.77 93.90
(x) 97.19 93.86
± S.D. 2.05 2.04
%RSD 2.11 2.04
%Error 1.22 1.18
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and GLM, respectively. Also, the inter-day precision was
determined by analyzing the same concentrations over
three successive days. The mean percentage recoveries
based on the average of three separate determinations
were 97.19 ± 2.05 and 93.86 ± 2.04 for ROS and GLM,
respectively. The results are abridged in Table 4. The
small values of %RSD and % Error indicates high preci-
sion and accuracy of the proposed method and its
applicability to human plasma samples.
Co-administered drugs
Effect of co-administered drugs such as pioglitazone,
nateglinide, metformine, glibenclamide and gliclazide
was studied. All of the studied drugs interfered with the
peak of either ROS or GLM. This necessities developing
other separation method.
Conclusion
The proposed HPLC method is applicable for the simul-
taneous separation and determination of ROS and GLM
in their co-formulated dosage forms. It has distinct
advantages over other existing method regarding sensi-
tivity, time saving and minimum detection limits. More-
over, it can be applied to the determination of both
drugs in spiked human plasma.
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